RETRACTED: The efficacy and safety of neubotulinumtoxinA for the treatment of forehead horizontal lines in Asians – A clinical, prospective, interventional, split‐face study
Skin Research and Technology · 2024
DOI: 10.1111/srt.13644 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Skin Research and Technology, 2024. Verfasst von Jessica Jane Sy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Asia-Pacific Aesthetic Academy, Seoul, Hong Kong. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents, Skin Aging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Botulinum toxin injections are widely sought after in the field of medical aesthetics, offering consumers a variety of brand choices. Two commonly available botulinum toxin products, onabotulinumtoxinA and neubotulinumtoxinA, are featured in numerous clinics, leading many to question whether there are discernible differences in results, given their varying price ranges.
Objective
To evaluate the efficacy and safety of neubotulinumtoxinA for the treatment of forehead horizontal lines.
Methods
A 12‐week prospective, single‐centre, interventional split‐face study was conducted, including 30 subjects. These enrolled subjects received a single treatment session, with neubotulinumtoxinA applied to the left side of the forehead and onabotulinumtoxinA to the right side. A superficial injection was performed in all individuals, where the product was injected subdermally in the frontalis muscle. Evaluation was conducted at baseline, 7 days, 14, days and 4, 8, and 12 weeks after treatment, both when the eyebrows were at maximum lift and in a resting position. Treatment efficacy was assessed by two physicians and self‐assessed by the patients, using the Fitzpatrick Wrinkle Classification system. Adverse events were documented to evaluate safety.
Results
The study found no statistically significant difference in the efficacy of neubotulinum and onabotulinum for treating forehead wrinkles, as indicated by p ‐values above 0.05 for both static and dynamic conditions. No safety and adverse events were observed in both formulations.
Conclusion
This study has demonstrated that neither formulation is inferior to each other in the treatment of forehead horizontal lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asia-Pacific Aesthetic Academy, Seoul, Hong Kong.
- Division in Anatomy and Developmental Biology, Department of Oral Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, South K…
- Maylin Clinic (Apgujeong), Seoul, South Korea.
Zitieren
APA
Sy, J. J., Wu, R., Wan, J., Kim, S. B., & Yi, K. H. (2024). RETRACTED: The efficacy and safety of neubotulinumtoxinA for the treatment of forehead horizontal lines in Asians – A clinical, prospective, interventional, split‐face study. Skin Research and Technology. https://doi.org/10.1111/srt.13644
Vancouver
Sy JJ, Wu R, Wan J, Kim SB, Yi KH. RETRACTED: The efficacy and safety of neubotulinumtoxinA for the treatment of forehead horizontal lines in Asians – A clinical, prospective, interventional, split‐face study. Skin Research and Technology. 2024. doi:10.1111/srt.13644
BibTeX
@article{Sy2024,
author = {Sy, Jessica Jane and Wu, Raymond and Wan, Jovian and Kim, Soo-Bin and Yi, Kyu-Ho},
title = {RETRACTED: The efficacy and safety of neubotulinumtoxinA for the treatment of forehead horizontal lines in Asians – A clinical, prospective, interventional, split‐face study},
journal = {Skin Research and Technology},
year = {2024},
doi = {10.1111/srt.13644}
}
EUVIMED